Kidswell Bio Corporation
The 45840 stock trades on Tokyo Stock Exchange (TSE/TYO)
Company Description
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
Drug Pipeline
Source: Kidswell Bio Corporation - 20221220
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
Darbepoetin alfa
Renal Disease
Reg/Com
Filgrastim
Acute Myeloid Leukemia
Reg/Com
Ranibizumab
Wet Age-Related Macular Degeneration
Reg/Com
0 Comments on 45840 stock
Newest
Conversation